WO2021259136A1 - 一种心房间的压力调节装置 - Google Patents
一种心房间的压力调节装置 Download PDFInfo
- Publication number
- WO2021259136A1 WO2021259136A1 PCT/CN2021/100650 CN2021100650W WO2021259136A1 WO 2021259136 A1 WO2021259136 A1 WO 2021259136A1 CN 2021100650 W CN2021100650 W CN 2021100650W WO 2021259136 A1 WO2021259136 A1 WO 2021259136A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- section
- stent
- middle section
- pressure regulating
- regulating device
- Prior art date
Links
- 230000003014 reinforcing effect Effects 0.000 claims abstract description 11
- 239000012528 membrane Substances 0.000 claims abstract description 5
- 230000001105 regulatory effect Effects 0.000 claims description 33
- 210000002837 heart atrium Anatomy 0.000 claims description 10
- 230000001746 atrial effect Effects 0.000 claims description 5
- 239000000560 biocompatible material Substances 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 description 14
- 210000005246 left atrium Anatomy 0.000 description 13
- 210000005245 right atrium Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 206010007559 Cardiac failure congestive Diseases 0.000 description 8
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 8
- 210000005242 cardiac chamber Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 241001111421 Pannus Species 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 230000004087 circulation Effects 0.000 description 4
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 3
- 210000004971 interatrial septum Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009125 cardiac resynchronization therapy Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229910001000 nickel titanium Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229910000619 316 stainless steel Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 229920010741 Ultra High Molecular Weight Polyethylene (UHMWPE) Polymers 0.000 description 1
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical class [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000003157 atrial septum Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- MMAADVOQRITKKL-UHFFFAOYSA-N chromium platinum Chemical compound [Cr].[Pt] MMAADVOQRITKKL-UHFFFAOYSA-N 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001692 polycarbonate urethane Polymers 0.000 description 1
- -1 polyethylene terephthalate Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000019270 symptomatic heart failure Diseases 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
Definitions
- the present invention relates to the technical field of medical equipment, in particular to a pressure regulating device for a cardiac chamber.
- Heart failure (heart failure) is abbreviated as heart failure, which refers to the failure of the systolic and/or diastolic dysfunction of the heart to fully discharge the blood from the veins to the heart, leading to blood stasis in the venous system and insufficient blood perfusion in the arterial system, which in turn causes the heart Circulatory disorders syndrome.
- Heart failure is a serious disease with a high incidence and fatality rate. According to the location of heart failure, it can be divided into left heart failure, right heart failure and total heart failure. According to the clinical manifestations of heart failure, it can also be classified as contractile.
- Heart failure and diastolic heart failure among which diastolic heart failure (DHF) accounts for about half of all heart failure patients.
- DHF diastolic heart failure
- CTR Cardiac resynchronization therapy
- LVAD left ventricular assist device
- the method of using cardiac interatrial shunt is a new solution for the treatment of heart failure.
- the program is to place a stoma at the atrial septum between the left atrium and right atrium of the patient, and implant a shunt device to form a shunt between the left and right atrium, which can be implanted.
- the incoming interatrial shunt device has been successfully used in patients with severe symptomatic heart failure. By diverting or shunting blood from the left atrium (LA) to the right atrium (RA), the pressure in the left atrium is reduced or prevented from rising (left atrium decompression).
- This program can prevent, alleviate or limit the symptoms, signs and syndromes related to pulmonary congestion, including severe shortness of breath, pulmonary edema, hypoxia, and so on.
- the shunt system involved in this solution needs to have good transportability and long-term stable blood flow. Relatively speaking, the smaller the overall size of the stent, the less difficult it is to transport. However, in order to ensure long-term stable blood flow, the stent needs to have sufficient orifice area and good radial support. How to balance the two elements of transportability and long-term stable blood circulation is an urgent problem for experts and scholars to solve.
- the existing shunt device needs further optimization in terms of structure and performance.
- CorviaMedical has designed an all-metal alloy stent for diastolic heart failure that is used for shunting the left atrium to the right atrium. It has good support and a large effective orifice area, so the blood flow can be fully guaranteed, but The size of the stent is large, so the size of the matching delivery catheter is also very large, which increases the difficulty of delivery.
- the product AFR of Occlutech, Germany uses a nickel-titanium wire braided structure, made into a shape similar to the ASD occluder, and leaves a stoma for shunting; however, the braided structure of this product has a lower stoma support force and is easier to endothelialize And it will grow together quickly, which will affect the shunting effect.
- the present invention provides an atrial pressure regulating device, which is a hollow structure with open ends as a whole, and includes a stent and a membrane covering the stent; the stent is a shrinkable and expandable
- the structure is divided into an inflow section, a middle section and an outflow section along its axial direction; wherein the diameter of the inflow section and the outflow section is larger than the diameter of the middle section in the expanded state of the stent, and the inflow section and the outflow section
- the diameter of one end connected to the middle section is smaller than the diameter of the end far away from the middle section; the middle section adopts a radial support force-reinforced structure.
- the middle section is a closed ring structure.
- the middle section includes a plurality of S-shaped reinforcing ribs arranged circumferentially, and both ends of the S-shaped reinforcing ribs are connected to the inflow section and the outflow section, respectively.
- the inflow section and the outflow section both include a plurality of first support rods arranged in a circumferential direction, and the first support rods are arranged parallel to the axial direction of the bracket; adjacent to the first support rods At least one first wave-shaped connecting piece is connected therebetween.
- the inflow section and the outflow section are connected to the intermediate section through the first support rod or the first wave-shaped connecting member.
- the bracket includes a plurality of second support rods arranged in a circumferential direction, and the second support rods are all inclined to one side with respect to the axial direction; at least one first support rod passes between adjacent second support rods. Two wavy connectors.
- the inclination angle of the second support rod relative to the axial direction is 20°-45°.
- a reinforcing rib is connected at the middle section between the adjacent second support rods.
- the maximum diameter of the inflow section is greater than the maximum diameter of the outflow section.
- the bracket is also provided with a fixing part for connecting the pressure regulating device of the atrium to the conveying device.
- the stent and the covering film are made of biocompatible materials.
- the covering film is wrapped on the stent, and skirts extend on both ends of the stent in the axial direction.
- it further includes at least one anchor, the anchor is arranged on the outer side wall of the pressure regulating device, and the end of the anchor extends to one side of the middle section and is separated from the atrial septal wall get in touch with.
- a U-shaped part is provided at the end of one end of the anchor extending to the middle section.
- the present invention has the following advantages and positive effects due to the adoption of the above technical solutions:
- the pressure regulating device for the cardiac chamber provided by the present invention by designing the middle section as a support-strength-strength structure, makes the middle section embedded in the interatrial septum ensure a large radial support force while ensuring the circulation performance, which can prevent the use of
- the displacement of the device can also prevent the device from being compressed and become smaller, ensuring a long-term stable blood flow, and avoiding the puncture hole from being closed again.
- the overall size of the pressure regulating device for the chamber of the heart provided by the present invention is still small, so the size of the matching delivery device is also correspondingly small, it is less traumatic to the human body, and has good transportability and operability.
- Figure 1 is a schematic diagram 1 of the overall structure of the pressure regulating device in the central room of the first embodiment
- FIG. 2 is a schematic diagram of the overall structure of the pressure regulating device in the central room of the embodiment 1;
- Figure 3 is a schematic diagram of the stent in embodiment 1 after being longitudinally sectioned and flattened;
- Figure 5 is the second schematic diagram of the fixing part mounted on the bracket in the first embodiment
- Figure 6 is a schematic diagram of the overall structure of the pressure regulating device in the central room of the second embodiment
- Figure 7 is a schematic diagram of the stent in Embodiment 2 after being longitudinally sectioned and flattened;
- Figure 8 is a schematic diagram of the overall structure of the pressure regulating device in the central room of the third embodiment.
- Figure 9 is a schematic diagram of the first embodiment of the stent in embodiment 3 after being longitudinally sectioned and flattened;
- Fig. 10 is a second schematic diagram of the stent in embodiment 3 after being longitudinally cut and flattened.
- the present invention provides a pressure regulating device for the atrium, which is a hollow structure with open ends, including a stent and a membrane covering the stent; the stent is a shrinkable and expandable structure along its axis It is divided into an inflow section 1, a middle section 2 and an outflow section 3.
- the diameter of the inflow section 1 and the outflow section 2 is larger than the diameter of the middle section 2, and the inflow section 1 and the outflow section 3 are connected to the middle section 2.
- the diameter of one end is smaller than the diameter of the end away from the middle section 2; the middle section 2 adopts a radial support force-reinforced structure.
- the pressure regulating device of the atrium When in use, the pressure regulating device of the atrium is compressed into the delivery device, and then delivered to the target location through the delivery device, so that the inflow section 1 is located in the left atrium, the outflow section 3 is located in the right atrium, and the middle section 2 is embedded in the two atria
- the outflow section 3 is at least 5mm deep into the right atrium, so that the outlet of the outflow section 3 is located outside the natural circulation flow path of blood entering the patient’s atrium from the inferior vena cava, so as to prevent the inferior cavity
- the embolus entrained in the venous flow is guided to the outlet of the outflow section 3.
- the pressure regulating device of the heart chamber After the pressure regulating device of the heart chamber is delivered to the target location, it changes from the contracted delivery state to the expanded expanded state after release, thereby forming a hollow structure for blood to flow from the left atrium to the right atrium.
- the pressure regulating device for the cardiac chamber provided by the present invention by designing the middle section 2 as a supporting force-enhanced structure, makes the middle section 2 embedded in the interatrial septum ensure a large radial supporting force when ensuring the circulation performance, which can prevent When the device is shifted in use, it can also prevent the device from being compressed and reduced, ensuring a long-term stable blood flow, and avoiding the puncture hole from being closed again. Moreover, the overall size of the pressure regulating device of the cardiac chamber provided by the present invention is still kept small, so the size of the matching delivery device is also correspondingly small, it is less traumatic to the human body, and has good transportability and operability.
- the middle section 2 is a closed ring structure; the closed ring structure can ensure the circumferential strength of the middle section 2 of the stent, and will not produce non-uniform deformation under external pressure. Maintain the effective passage area of the stent and improve blood flow.
- the width of the ring structure in the axial direction can be adjusted according to the thickness of the heart tissue, which is not limited here.
- the structures of the inflow section 1 and the outflow section 3 of the stent are the same; specifically, the inflow section 1 includes a plurality of first support rods 101 evenly distributed in the circumferential direction, and the first support rods 101 are parallel In the axial arrangement of the stent, one end of the first support rod 101 is connected to the middle section 2; at least one first wave-shaped connecting member 102 is connected between adjacent first support rods 101, thereby forming an annular support structure, which ensures The circumferential strength and compliance of the inflow section of the stent.
- first wave-shaped connectors 102 are connected between adjacent first support rods 101.
- first wave-shaped connectors 102 between adjacent first support rods 101.
- the number of settings can be adjusted according to factors such as the length of the first support rod 101, and there is no limitation here.
- each of the first wave-shaped connecting members 102 located in the same radial direction constitutes a continuous wave shape; the first wave-shaped connecting member 102 is connected to the connection point of the first support rod 101.
- the outflow section 3 also includes a plurality of first support rods 201 evenly distributed in the circumferential direction.
- a first wave-shaped connecting member 202 is provided between adjacent first support rods 201, and the connection relationship between them is equal. Please refer to the structure description in the inflow section 1, which will not be repeated here.
- the inflow section 1, the middle section 2 and the outflow section 3 of the stent are made in one piece.
- the maximum diameter of the inflow section 1 is greater than the maximum diameter of the outflow section 3.
- the pressure at the large section is high; based on the above principle, in this embodiment, it is preferable to set the diameter of the blood inlet of the inflow section 1 of the stent to be larger than the diameter of the blood outlet of the outflow section 3, so that the pressure on the left atrial side is greater than that on the right atrium Pressure facilitates the flow of blood from the left atrium into the right atrium and prevents blood reflux.
- the length L1 of the inflow section 1 is 3-10mm, and the inner diameter D1 of the inflow end is 10-20mm; the length L2 of the middle section 2 is 1-2mm, and its minimum inner diameter D2 is 4-8mm, preferably 5-6.5mm ; The length L3 of the outflow section 3 is 5-10mm, and the inner diameter D3 of the outflow end is 9-15mm.
- the size of each section of the bracket can be adjusted according to specific conditions, and there is no limitation here.
- the stent can be made of Nitinol, titanium alloy, cobalt chromium alloy, MP35n, 316 stainless steel, L605, Phynox/Elgiloy, platinum chromium, or other biocompatible metals as known to those skilled in the art. It is made of biocompatible metal frame or laser-cut solid metal tube.
- the stent is made of a shape memory alloy, but optionally, it also includes materials that can be elastically or plastically deformed, such as a balloon expandable, or can respond to temperature changes in a contracted delivery state and expanded deployment. Shape memory alloys that transition between states. More preferably, the distance, thickness, composition and/or growth pattern of pannus can be controlled by increasing the surface finish of the stent. For example, the outer surface of the stent can be electropolished to inhibit pannus formation.
- an anchor 4 is also provided on the stent, and the anchor 4 is bent to the side of the interatrial septum after being released.
- the pressure regulating device is used to divert or shunt blood from the left atrium (LA) to the right atrium (RA) to reduce the pressure in the left atrium.
- the blood flow through the fossa ovale will generate pressure.
- the shape of the fossa ovale may be irregular or gradually grow into an irregular shape. These factors may cause the pressure regulating device to tilt or shake, in order to prevent the device from being unpredictable.
- the adverse effect caused by tilting or shaking can be at one or several positions in the middle section near the outflow section (shown in Figure 4), the middle section near the inflow section, the outflow section (shown in Figure 5), and the inflow section. Set up anchors.
- the anchor of this embodiment can also be a U-shaped inverted end 5 that contacts but does not penetrate the atrial septal wall in a fully expanded state; preferably, the anchor 4 is completely encapsulated with a polymer material, which can prevent pannus Formation.
- the covering film is made of biocompatible materials.
- the biocompatible material may be a polymer, such as expanded polytetrafluoroethylene (ePTFE), polyurethane, DACRON (polyethylene terephthalate), silicone, polycarbonate polyurethane (polycarbonate urethane) , Ultra-high molecular weight polyethylene (UHMWPE) or PTFE, it can also be metal, ceramic, carbon nanotube array or any other suitable material known to those skilled in the art to provide the following properties for pressure regulating devices.
- the covering film can use suitable biocompatible adhesives, sintering techniques, electrospinning techniques, etc. to sandwich the stent in the biocompatible material.
- the covering film may include ePTFE with an internode distance of up to 30 microns, with an inner layer and an outer layer, which are sintered together to form an integrated cavity; the present invention is not limited to the use of other packages Sealing methods and other suitable polymers to prevent transmural ingrowth of pannus tissue.
- One of the purposes of the biocompatible cover is to form a closed cavity, where the cover is used as a barrier to separate the stent from the outside of the pressure regulating device, but the fixing ear (a specific implementation structure of the fixing part) is bare metal, that is, there is no Cladding.
- the membrane is coated on the stent, and skirts are extended on both ends of the stent in the axial direction.
- the arrangement of the skirts can promote laminar flow and limit the pannus inward during the healing of the pressure regulating device. Grow.
- this embodiment is an adjustment based on the first embodiment.
- the middle section includes a plurality of circumferentially arranged S-shaped reinforcing ribs 201; the shape and size of the S-shaped reinforcing ribs 201 can be adjusted to ensure that they are close to each other to form a similar circular inner wall, which improves the middle section of the bracket. At the same time, it ensures that the stent will not deform unevenly under external pressure, maintains the effective passage area of the stent, and improves blood flow.
- the structures of the inflow section 1 and the outflow section 3 of the stent are the same;
- the specific inflow section 1 includes a plurality of first support rods 103 evenly distributed in the circumferential direction, and the first support rods 103 are parallel to
- the stent is arranged in the axial direction; at least one first wave-shaped connector 104 is connected between adjacent first support rods 103 to form an annular support structure, which ensures the circumferential strength and compliance of the inflow section of the stent.
- a first wave-shaped connecting piece 104 is connected at both ends, and the first wave-shaped connecting piece 104 near the middle section 2 is opposite to the S-shaped reinforcing rib 201 connect.
- each of the first wave-shaped connecting members 104 located in the same radial direction constitutes a continuous wave shape; the first wave-shaped connecting member 104 is connected to the connection point of the first support rod 103.
- the outflow section 3 also includes a plurality of first support rods 203 evenly distributed in the circumferential direction, and a first wave-shaped connecting member 204 is provided between adjacent first support rods 203, and the connection relationship between them is the same. Refer to the description of the structure in the inflow section 1, and there is no restriction here.
- the rest of the structure of the pressure regulating device in the cardiac chamber can refer to the description in Embodiment 1, and it is not limited here.
- this embodiment is an adjustment based on the first embodiment.
- the bracket includes a plurality of second support rods 6 evenly distributed in the circumferential direction, and the second support rods 6 are arranged obliquely to one side with respect to the axial direction; at least one second support rod passes between adjacent second support rods.
- the wave-shaped connecting piece 7 forms a spiral cylindrical structure, and a plurality of second support rods 6 form an intermediate section, and the inclination direction of the second support rods 6 can be adjusted as required to design a normal spiral or a reverse spiral.
- the preferred inclination angle of the second support rod with respect to the axial direction is 20°-45°.
- a second wave-shaped connecting piece 7 is connected to both ends of the preferred second support rod 6.
- a reinforcing rib 8 is connected at the middle section between adjacent second support rods 6 to form an annular inner wall, which can further improve the circumferential strength of the middle section of the stent. There is no non-uniform deformation under external pressure, which can maintain the effective passage area of the stent and improve blood flow.
- the rest of the structure of the pressure regulating device in the cardiac chamber can refer to the description in Embodiment 1, and it is not limited here.
Abstract
Description
Claims (14)
- 一种心房间的压力调节装置,其特征在于,整体呈两端开口的中空结构,包括支架和覆于所述支架上的覆膜;所述支架为一可收缩扩张结构,沿其轴向分为流入段、中间段和流出段;其中,在所述支架扩张状态下所述流入段、流出段的直径大于所述中间段的直径,所述流入段、流出段连接所述中间段一端的直径小于远离所述中间段一端的直径;所述中间段采用径向支撑力加强型结构。
- 根据权利要求1所述的心房间的压力调节装置,其特征在于,所述中间段为闭合的圆环结构。
- 根据权利要求1所述的心房间的压力调节装置,其特征在于,所述中间段包括多个周向布置的S型加强筋,且所述S型加强筋的两端分别连接到所述流入段和所述流出段上。
- 根据权利要求1或2或3所述的心房间的压力调节装置,其特征在于,所述流入段、流出段均包括有多个周向布置的第一支撑杆,且所述第一支撑杆平行于所述支架的轴向设置;相邻所述第一支撑杆之间连接有至少一个第一波浪形连接件。
- 根据权利要求4所述的心房间的压力调节装置,其特征在于,所述流入段、流出段通过所述第一支撑杆或所述第一波浪形连接件与所述中间段连接。
- 根据权利要求1所述的心房间的压力调节装置,其特征在于,所述支架包括有多个周向布置的第二支撑杆,且所述第二支撑杆相对于轴向均向一侧倾斜设置;相邻第二支撑杆之间通过至少一个第二波浪形连接件。
- 根据权利要求6所述的心房间的压力调节装置,其特征在于,所述第二支撑杆相对于轴向的倾斜角度为20°-45°。
- 根据权利要求6或7所述的心房间的压力调节装置,其特征在于,相邻所述第二支撑杆之间在中间段处连接有加强筋。
- 根据权利要求1所述的心房间的压力调节装置,其特征在于,在所述支架扩张状态下,所述流入段的最大直径大于所述流出段的最大直径。
- 根据权利要求1所述的心房间的压力调节装置,其特征在于,所述支架上还设有用于将所述心房间的压力调节装置连接到输送装置上的固定部。
- 根据权利要求1所述的心房间的压力调节装置,其特征在于,所述支架和所述覆膜采用生物相容性材料制成。
- 根据权利要求1所述的心房间的压力调节装置,其特征在于,所述覆膜包覆在所述支架上,且在所述支架轴向上的两端上延伸有裙边。
- 根据权利要求1所述的心房间的压力调节装置,其特征在于,还包括至少一个锚固件,所述锚固件设置在所述压力调节装置的外侧壁上,且所述锚固件的端部向所述中间段一侧延伸设置,并与心房间隔壁接触。
- 根据权利要求13所述的心房间的压力调节装置,其特征在于,所述锚固件向所述中间段延伸的一端的末端设置有U型部。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010584888.3 | 2020-06-23 | ||
CN202010584888.3A CN113827373A (zh) | 2020-06-23 | 2020-06-23 | 一种心房间的压力调节装置 |
CN202021189796.7U CN212879683U (zh) | 2020-06-23 | 2020-06-23 | 一种心房间的压力调节装置 |
CN202021189796.7 | 2020-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021259136A1 true WO2021259136A1 (zh) | 2021-12-30 |
Family
ID=79281935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/100650 WO2021259136A1 (zh) | 2020-06-23 | 2021-06-17 | 一种心房间的压力调节装置 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021259136A1 (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102458316A (zh) * | 2009-04-28 | 2012-05-16 | Dc设备公司 | 治疗心力衰竭的装置、系统和方法 |
US20130030521A1 (en) * | 2011-07-28 | 2013-01-31 | Yaacov Nitzan | Devices for reducing left atrial pressure having biodegradable constriction, and methods of making and using same |
CN105555204A (zh) * | 2013-05-21 | 2016-05-04 | V-波有限责任公司 | 用于递送减小左房压力的装置的设备 |
CN109259894A (zh) * | 2017-07-18 | 2019-01-25 | 杭州诺生医疗科技有限公司 | 心房间的压力调节装置 |
US10463477B2 (en) * | 2015-11-09 | 2019-11-05 | Corvia Medical, Inc. | Retrievable devices for treating heart failure |
CN110536657A (zh) * | 2017-03-03 | 2019-12-03 | V-波有限责任公司 | 用于重新分配心房血量的分流器 |
CN112155790A (zh) * | 2020-10-28 | 2021-01-01 | 启晨(上海)医疗器械有限公司 | 一种房间隔分流减压装置 |
CN212879683U (zh) * | 2020-06-23 | 2021-04-06 | 上海派孚医疗科技有限公司 | 一种心房间的压力调节装置 |
-
2021
- 2021-06-17 WO PCT/CN2021/100650 patent/WO2021259136A1/zh active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102458316A (zh) * | 2009-04-28 | 2012-05-16 | Dc设备公司 | 治疗心力衰竭的装置、系统和方法 |
US20130030521A1 (en) * | 2011-07-28 | 2013-01-31 | Yaacov Nitzan | Devices for reducing left atrial pressure having biodegradable constriction, and methods of making and using same |
CN105555204A (zh) * | 2013-05-21 | 2016-05-04 | V-波有限责任公司 | 用于递送减小左房压力的装置的设备 |
US10463477B2 (en) * | 2015-11-09 | 2019-11-05 | Corvia Medical, Inc. | Retrievable devices for treating heart failure |
CN110536657A (zh) * | 2017-03-03 | 2019-12-03 | V-波有限责任公司 | 用于重新分配心房血量的分流器 |
CN109259894A (zh) * | 2017-07-18 | 2019-01-25 | 杭州诺生医疗科技有限公司 | 心房间的压力调节装置 |
CN212879683U (zh) * | 2020-06-23 | 2021-04-06 | 上海派孚医疗科技有限公司 | 一种心房间的压力调节装置 |
CN112155790A (zh) * | 2020-10-28 | 2021-01-01 | 启晨(上海)医疗器械有限公司 | 一种房间隔分流减压装置 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11135410B2 (en) | Devices and methods for treating heart failure | |
US11241237B2 (en) | Left atrial appendage closure implant | |
EP2600798B1 (en) | Two valve caval stent for functional replacement of incompetent tricuspid valve | |
CN106420114A (zh) | 一种心脏瓣膜假体 | |
KR102563467B1 (ko) | 카테터경유 폐의 볼 판막 조립체 | |
JP7322133B2 (ja) | シャント、閉塞器、開窓のためのメディカルデバイスならびに関連するシステム及び方法 | |
EP3573577B1 (en) | Device for treatment and prevention of fluid overload in patients with heart failure | |
CN112754733B (zh) | 心脏瓣膜 | |
CN112469365A (zh) | 用于流体流控制的可植入医疗设备 | |
US11406517B2 (en) | Vascular stent | |
CN112512461A (zh) | 限流支架移植物 | |
US20240065698A1 (en) | Left atrial appendage closure implant | |
CN113924138B (zh) | 用于急性治疗在患有心力衰竭的患者体内的流体超负荷的方法和装置 | |
CN109966023A (zh) | 心脏瓣膜假体及其支架 | |
WO2021259136A1 (zh) | 一种心房间的压力调节装置 | |
CN212879683U (zh) | 一种心房间的压力调节装置 | |
CN107019581B (zh) | 一种升主动脉主动脉瓣一体化血管内支架 | |
CN111772878A (zh) | 一种心脏瓣膜假体 | |
CN112469364A (zh) | 流量减少支架移植物 | |
WO2022012010A1 (zh) | 一种心脏瓣膜假体 | |
CN113827373A (zh) | 一种心房间的压力调节装置 | |
CN211213278U (zh) | 一种带瓣膜的房间隔分流装置 | |
WO2022267210A1 (zh) | 一种人工心脏瓣膜及其输送系统 | |
WO2022178740A1 (zh) | 一种外周血管支架及其制备方法和应用 | |
CN116098739A (zh) | 一种具有锚定结构的主动脉瓣膜支架 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21828267 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21828267 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 07/06/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21828267 Country of ref document: EP Kind code of ref document: A1 |